Please click HERE to view the abstract criteria and guidelines.
Registration for this event will be made available shortly.
The UK Oncology Nursing Society (UKONS) Passport for the Safe Handling and Administration of Systemic Anti-Cancer Therapies (SACT) is now available. To view the passport, please click HERE or to order your physical copy, click HERE
Click HERE to access more information about the award-winning 24 hour triage rapid assessment and access toolkit and to order copies of the toolkit.
Closed-system drug-transfer devices in addition to safe handling of hazardous drugs versus safe handling alone for reducing healthcare staff exposure to infusional hazardous drugs
UKONS position statement
In 2016 at their annual conference UKONS were requested by our members to provide some guidance on the effectiveness of closed-system drug transfer devices (CSTD) in addition to safe handling of hazardous drugs versus safe handling alone for reducing healthcare staff exposure to infusional hazardous drugs.
In response to this request UKONS commissioned a Cochrane systematic review to provide us with independent high quality, robust research to provide sufficient and unambiguous information on the potential benefits and costs of CSTD to inform a position statement which we are delighted to announce has now been published.
To read the full position statement, please click HERE
Gilead UK and Ireland Fellowship Programme
Applicant call now open
Gilead are pleased to announce that the 2018 Gilead UK and Ireland Fellowship Programme is now open for grant applications in both invasive fungal disease (IFD) and oncology. The objective of the Gilead UK & Ireland Fellowship Programme is to support initiatives to improve patient care in the fields of HIV, viral hepatitis, oncology/haematology, respiratory and invasive fungal disease.
The Fellowship Programme aims to encourage the development, exploration and dissemination of new ideas which generate and promote best practice in the delivery of patient-centred care through innovative and reproducible models.
National Chemotherapy Board (NCB) GOOD PRACTICE GUIDELINE: Promoting Early Identification of Systemic Anti-Cancer Therapies Side Effects: – Two Approaches.
This guidance has been produced by the National Chemotherapy Board in response to concerns that patients often delay reporting serious Systemic Anti-Cancer Therapy (SACT) side effects to dedicated help lines. Two complementary approaches to improve side effect reporting are suggested:
1. Empowerment focuses on equipping patients to take responsibility for identifying and reporting important side effects and may be mediated via technology.
2. Proactive monitoring includes clinician interventions (e.g. telephone support or home visits).
The NCB Good Practice Guidelines are available HERE
Morbidity and mortality within 30 days of Systemic Anti-Cancer Therapy (SACT): Review of Current Practice suggested Standardised Review Process May 2016.
The importance of having mortality meetings to review deaths within 30-days of SACT has been well established. The National Chemotherapy Board (NCB) have recognised that whilst there are many examples of good practice there was inconsistency of approach between centres which may limit sharing of learning. The NCB have summarised the key details of the processes currently being used and have developed a proposed template for an operational policy and proforma.
Please click HERE for the covering letter and click HERE for the accompanying document
Click hereto read the UKONS paper on 'Best practice in nurse-led chemotherapy review: a position statement' at ecancer.org, or download the pdf